A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Conditions
Cerebral Amyloid Angiopathy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Clinical Trial Site, Los Angeles, California, United States
Clinical Trial Site, Orange, California, United States
Clinical Trial Site, Palo Alto, California, United States
Clinical Trial Site, Sacramento, California, United States
Clinical Trial Site, San Francisco, California, United States
Clinical Trial Site, Aurora, Colorado, United States
Clinical Trial Site, New Haven, Connecticut, United States
Clinical Trial Site, Gainesville, Florida, United States
Clinical Trial Site, Jacksonville, Florida, United States
Clinical Trial Site, Maitland, Florida, United States
Clinical Trial Site, Naples, Florida, United States
Clinical Trial Site, Chicago, Illinois, United States
Clinical Trial Site, Lexington, Kentucky, United States
Clinical Trial Site, New Orleans, Louisiana, United States
Clinical Trial Site, Boston, Massachusetts, United States
Clinical Trial Site, Plymouth, Massachusetts, United States
Clinical Trial Site, Rochester, Minnesota, United States
Clinical Trial Site, St Louis, Missouri, United States
Clinical Trial Site, Hackensack, New Jersey, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, Durham, North Carolina, United States
Clinical Trial Site, Canton, Ohio, United States
Clinical Trial Site, Cleveland, Ohio, United States
Clinical Trial Site, Abington, Pennsylvania, United States
Clinical Trial Site, Philadelphia, Pennsylvania, United States
Clinical Trial Site, Pittsburgh, Pennsylvania, United States
Clinical Trial Site, Dallas, Texas, United States
Clinical Trial Site, Dallas, Texas, United States
Clinical Trial Site, Houston, Texas, United States
Clinical Trial Site, San Antonio, Texas, United States
Clinical Trial Site, Seattle, Washington, United States
Clinical Trial Site, Adelaide, Australia
Clinical Trial Site, Brisbane, Australia
Clinical Trial Site, Heidelberg, Australia
Clinical Trial Site, Nedlands, Australia
Clinical Trial Site, Parkville, Australia
Clinical Trial Site, Calgary, Canada
Clinical Trial Site, Hamilton, Canada
Clinical Trial Site, Kelowna, Canada
Clinical Trial Site, Moncton, Canada
Clinical Trial Site, Montreal, Canada
Clinical Trial Site, Montreal, Canada
Clinical Trial Site, Ottawa, Canada
Clinical Trial Site, Toronto, Canada
Clinical Trial Site, Victoria, Canada
Clinical Trial Site, Amsterdam, Netherlands
Clinical Trial Site, Leiden, Netherlands
Clinical Trial Site, Nijmegen, Netherlands
Clinical Trial Site, Bern, Switzerland
Clinical Trial Site, Geneva, Switzerland
Clinical Trial Site, Sankt Gallen, Switzerland
Clinical Trial Site, Glasgow, United Kingdom
Clinical Trial Site, London, United Kingdom
Clinical Trial Site, London, United Kingdom
Study leads
Medical Director
Study Director
Alnylam Pharmaceuticals